These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 26028357)

  • 1. Effect of Cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors.
    Probst-Schendzielorz K; Viviani R; Stingl JC
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1219-32. PubMed ID: 26028357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.
    Hicks JK; Bishop JR; Sangkuhl K; Müller DJ; Ji Y; Leckband SG; Leeder JS; Graham RL; Chiulli DL; LLerena A; Skaar TC; Scott SA; Stingl JC; Klein TE; Caudle KE; Gaedigk A;
    Clin Pharmacol Ther; 2015 Aug; 98(2):127-34. PubMed ID: 25974703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study.
    Ricardo-Silgado ML; Singh S; Cifuentes L; Decker PA; Gonzalez-Izundegui D; Moyer AM; Hurtado MD; Camilleri M; Bielinski SJ; Acosta A
    BMC Med; 2022 Jul; 20(1):261. PubMed ID: 35879764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP450 genotype and aggressive behavior on selective serotonin reuptake inhibitors.
    Ekhart C; Matic M; Kant A; van Puijenbroek E; Schaik RV
    Pharmacogenomics; 2017 May; 18(7):613-620. PubMed ID: 28470107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
    Zhou SF
    Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reboxetine and cytochrome P450--comparison with paroxetine treatment in humans.
    Kuhn UD; Kirsch M; Merkel U; Eberhardt AM; Wenda B; Maurer I; Härtter S; Hiemke C; Volz HP; Balogh A
    Int J Clin Pharmacol Ther; 2007 Jan; 45(1):36-46. PubMed ID: 17256449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.
    Preskorn SH
    Clin Pharmacokinet; 1997; 32 Suppl 1():1-21. PubMed ID: 9068931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Completed suicides of citalopram users-the role of CYP genotypes and adverse drug interactions.
    Rahikainen AL; Vauhkonen P; Pett H; Palo JU; Haukka J; Ojanperä I; Niemi M; Sajantila A
    Int J Legal Med; 2019 Mar; 133(2):353-363. PubMed ID: 30173302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs).
    Matchar DB; Thakur ME; Grossman I; McCrory DC; Orlando LA; Steffens DC; Goldstein DB; Cline KE; Gray RN
    Evid Rep Technol Assess (Full Rep); 2007 Jan; (146):1-77. PubMed ID: 17764209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.
    Bousman CA; Stevenson JM; Ramsey LB; Sangkuhl K; Hicks JK; Strawn JR; Singh AB; Ruaño G; Mueller DJ; Tsermpini EE; Brown JT; Bell GC; Leeder JS; Gaedigk A; Scott SA; Klein TE; Caudle KE; Bishop JR
    Clin Pharmacol Ther; 2023 Jul; 114(1):51-68. PubMed ID: 37032427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine.
    McAlpine DE; Biernacka JM; Mrazek DA; O'Kane DJ; Stevens SR; Langman LJ; Courson VL; Bhagia J; Moyer TP
    Ther Drug Monit; 2011 Feb; 33(1):14-20. PubMed ID: 21099743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes.
    Berle JØ; Steen VM; Aamo TO; Breilid H; Zahlsen K; Spigset O
    J Clin Psychiatry; 2004 Sep; 65(9):1228-34. PubMed ID: 15367050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.
    Baumann P
    Clin Pharmacokinet; 1996 Dec; 31(6):444-69. PubMed ID: 8968657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update.
    Hemeryck A; Belpaire FM
    Curr Drug Metab; 2002 Feb; 3(1):13-37. PubMed ID: 11876575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with fluoxetine and norfluoxetine plasma concentrations and clinical response in Mexican patients with mental disorders.
    Sagahón-Azúa J; Medellín-Garibay SE; Chávez-Castillo CE; González-Salinas CG; Milán-Segovia RDC; Romano-Moreno S
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00864. PubMed ID: 34523245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.
    Ereshefsky L; Riesenman C; Lam YW
    Clin Pharmacokinet; 1995; 29 Suppl 1():10-8; discussion 18-9. PubMed ID: 8846618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotyping of patients treated with selective serotonin reuptake inhibitors.
    Solhaug V; Haslemo T; Kringen MK; Molden E; Dietrichs ES
    Tidsskr Nor Laegeforen; 2022 Sep; 142(13):. PubMed ID: 36164782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review.
    Vaswani M; Linda FK; Ramesh S
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Feb; 27(1):85-102. PubMed ID: 12551730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.
    Azuma J; Hasunuma T; Kubo M; Miyatake M; Koue T; Higashi K; Fujiwara T; Kitahara S; Katano T; Hara S
    Eur J Clin Pharmacol; 2012 Jan; 68(1):29-37. PubMed ID: 21739267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.
    Scordo MG; Spina E; Dahl ML; Gatti G; Perucca E
    Basic Clin Pharmacol Toxicol; 2005 Nov; 97(5):296-301. PubMed ID: 16236141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.